Ozempic, Wegovy, and Saxenda are under investigation by the European Medicines Agency for possibly causing consumers to self-harm or experience suicidal thoughts. Clinical trials of the drug did not see this to be a large risk factor, but experts note a changing population of those taking the drugs may have shifted risk levels.